CBU
ARQT icon

CIBC Bancorp USA’s Arcutis Biotherapeutics ARQT Stock Holding History

CIBC Bancorp USA’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$387K Buy
14,759
+783
+6% +$18.2K ﹤0.01% 1402
2026
Q1 		$329K Buy
+13,976
New +$357K ﹤0.01% 1371
2025
Q3 		$215K Buy
+11,417
New +$180K ﹤0.01% 1225

Other funds holding ARQT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

CIBC Bancorp USA's ARQT Position: Q2 2026 in Review

CIBC Bancorp USA increased its Arcutis Biotherapeutics (ARQT) stake by 5.6% in Q2 2026, buying an estimated $18.2K and bringing the position to 14,759 shares worth $387K. The position accounts for ﹤0.01% of the portfolio, ranked #1402.

CIBC Bancorp USA first reported a position in ARQT in Q3 2025 and has held it in 3 quarters since. 249 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • CIBC Bancorp USA held 14,759 shares of Arcutis Biotherapeutics worth $387K as of Q2 2026.
  • CIBC Bancorp USA bought 783 Arcutis Biotherapeutics shares in Q2 2026, an estimated $18.2K.
  • Arcutis Biotherapeutics made up ﹤0.01% of CIBC Bancorp USA's portfolio in Q2 2026, its #1402 holding.
  • CIBC Bancorp USA first reported a position in Arcutis Biotherapeutics in Q3 2025 and has held it in 3 quarters since.
  • 249 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on CIBC Bancorp USA's 13F filing for Q2 2026, filed 13 Aug 2026.